Download PDF
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2018; 54(02): 106-113
DOI: 10.1055/s-0040-1712793
Original Article

New Perspective of Lymphatic Filariasis-Towards Elimination

Shantanu Kumar Kar
IMS & SUM Hospital, Siksha ‘O’ Anusandhan University, Bhubaneswar, Odisha.
,
Jagadish Hansa
IMS & SUM Hospital, Siksha ‘O’ Anusandhan University, Bhubaneswar, Odisha.
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

ABSTRACT

Lymphatic filariasis (LF) is an important public health problem globally as well as in India. LF causes both acute and chronic morbidity with significant impediment to socio-economic development. The aim of this review was to analyze the current scenario in filariasis research. This debilitating disease which carried a serious social stigma and once thought to be difficult to treat, control, and eradicate, now could achieve significant success in its treatment and elimination globally by 2020, including from India. Achievement of success so far could be possible through series of evolution in understanding pathology of the disease, pathogenesis of the etiologic agent parasite, diagnostic tools, therapeutic and preventive approaches through new knowledge, techniques and development of investigative tools.

Keywords:

Lymphatic filariasis - W.bancrofti - lymphedema


Publication History

Article published online:
08 May 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Rebollo MP, Bockarie MJ (2017). Can lymphatic filariasis be eliminated by 2020? Trends Parasitol 33(2): 83-92.
  • 2 Zeldenryk L, Gordon S, Gray M, Speare R, Melrose W (2012). Disability measurement for lymphatic filariasis: a review of generic tools used within morbidity management programs. PLoS Negl Trop Dis 6(9): e1768.
  • 3 Stillwaggon E, Sawers L, Rout J, Addiss D, Fox LA(2016). Economic costs and benefits of a community-based lymphedema management program for lymphatic filariasis in Odisha state, India. Am J Trop Med Hyg 95(4): 877-884.
  • 4 WHO (2012) Global programme to eliminate lymphatic filariasis: progress report, 2011. Wkly Epidemiology Red 87: 346–356 Available: http://www.who.int/wer/2012/wer8737.pdf.
  • 5 WHO (2014). Global programme to eliminate lymphatic filariasis: progress report. Wkly Epidemiol Rec 89: 409-418.
  • 6 WHO (2015). Global programme to eliminate lymphatic filariasis: progress report. Wkly Epidemiol Rec 90: 489-504.
  • 7 Michael E, Bundy DA, Grenfell BT (1996). Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology 112: 409–428.
  • 8 Suma TK (2013). Indian scenario of elimination of lymphatic filariasis. Chapter 3. http://www.apiindia.org/medicine_update_2013/chap03.pdf.
  • 9 WHO (1995). Bridging the gaps. World Health Report. World Health Organization, Geneva, Switzerland. https://www.who.int/whr/1995/en/whr95_en.pdf.
  • 10 Ramaiah KD, Das PK, Michael E, Guyatt H (2000). The economic burden of lymphatic filariasis in India. Parasitol Today 16: 251-253.
  • 11 Kar SK, Mania J, Baldwin C, Denham DA (1992). The sheath of microfilaria of Wuchereria bancrofti has albumin and immunoglobin on its surface. Parasite Immunol 15: 297-300.
  • 12 Kar SK (1985). Lymphatic nodules in human filariasis. Lymphology 18(4): 163-164.
  • 13 Kar SK (1986). Atypical features in lymphatic filariasis. Indian J Med Res 84: 270-274.
  • 14 Webster EH (1943). Filariasis among white immigrants in Samoa. US Naval Med Bull 46: 186-192.
  • 15 Das PK, Srividya A, Pani SP, Ramaiah KD, Vanamail P, Dhanda V (1994). Cumulative exposure and its relationship with chronic filarial disease in bancroftian filariasis. Southeast Asian J Trop Med Pub Health 25: 516-521.
  • 16 WHO (1984). Fourth report of the WHO expert committee on filariasis. WHO Technical Report Series 702. Geneva: WHO. https://apps.who.int/iris/bitstream/handle/10665/39063/WHO_TRS_702.pdf
  • 17 Kar SK, Mania J, Kar PK (1993). Humoral immune response during filarial fever in Bancroftian filariasis. Trans R Soc Trop Med Hyg 87: 230-233.
  • 18 Gyapong JO, Gyapong M, Evans DB, Aikins MK, Adjei S (1996). The economic burden of lymphatic filariasis in northern Ghana. Ann Trop Med Parasitol 90: 39–48.
  • 19 Dreyer G, Medeiros Z, Netto MJ, Leal NC, de Castro LG, Piessens WF (1999). Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg 93: 413–417.
  • 20 Kar SK, DwibediB, Das BK, Agrawala BK, Ramachandran CP, Horton J (2017). Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment. PLoS Negl Trop Dis 11(10): e0005631.
  • 21 Kar SK, Mania J, Patnaik S (1994). The use of ivermectin for scabies. Natl Med J India 7: 15-16.
  • 22 Kar SK, Dwibedi B, Kerketa AS, et al (2015). A Randomized controlled trial of increased dose and frequency of albendazole with standard dose DEC for treatment of Wuchereria bancrofti microfilaremics in Odisha, India. PLoS Negl Trop Dis 9(3): e0003583.